Review article: therapeutic bile acids and the risks for hepatotoxicity

被引:53
作者
Ashby, K. [1 ]
Almario, E. E. Navarro [2 ]
Tong, W. [1 ]
Borlak, J. [3 ]
Mehta, R. [4 ]
Chen, M. [1 ]
机构
[1] US FDA, Div Bioinformat & Biostat, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA
[2] US FDA, Off Computat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[3] Hannover Med Sch, Ctr Pharmacol & Toxicol, Hannover, Germany
[4] US FDA, Div Gastroenterol & Inborn Error Prod, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
关键词
PRIMARY BILIARY-CIRRHOSIS; FARNESOID-X-RECEPTOR; FAMILIAL INTRAHEPATIC CHOLESTASIS; NATIONAL COOPERATIVE GALLSTONE; INDUCED LIVER FIBROSIS; LONG-TERM TREATMENT; CHENODEOXYCHOLIC ACID; LITHOCHOLIC ACID; URSODEOXYCHOLIC ACID; OBSTRUCTIVE-CHOLESTASIS;
D O I
10.1111/apt.14678
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background: Bile acids play important roles in cholesterol metabolism and signal through farnesoid X receptor and G protein-coupled receptors. Given their importance in liver biology, bile acid therapy enables therapeutic applications beyond the treatment of cholestatic liver disease. However, predicting hepatotoxicity of bile acids in humans is obscured due to inconsistent extrapolations of animal data to humans. Aim: To review the evidence that could explain discordant bile acids hepatotoxicity observed in humans and animals. Method: Literature search was conducted in PubMed using keywords bile acid, transporter, hepatotoxicity, clinical study, animal study, species difference, mechanism, genetic disorder. Relevant articles were selected for review. Results: Clinically significant hepatotoxicity was reported in response to certain bile acids, namely chenodeoxycholic acid, which was given a boxed warning for potential hepatotoxicity. The chemical structure, specifically the number and orientation of hydroxyl groups, significantly affects their hydrophobicity, an important factor in bile acid toxicity. Experimental studies show that hydrophobic bile acids can lead to liver injury through various mechanisms, such as death receptor signalling, mitochondrial dysfunction and inflammation. Although animal studies play a central role in investigating bile acid safety, there are considerable differences in bile acid composition, metabolism and hepatobiliary disposition across species. This does not allow appropriate safety inference, especially for predicting hepatotoxicity in humans. Exploring evidences stemming from inborn errors, genetic models of disease and toxicology studies further improves an understanding of bile acid hepatotoxicity. Conclusion: Species differences should be considered in the development of bile acid related therapeutics. Although the mechanism of bile acid hepatotoxicity is still not fully understood, continued mechanistic studies will deepen our understanding.
引用
收藏
页码:1623 / 1638
页数:16
相关论文
共 116 条
[1]
BILE-ACID MALABSORPTION AND BILE-ACID DIARRHEA IN INTESTINAL RESECTION [J].
ALDINI, R ;
RODA, A ;
FESTI, D ;
SAMA, C ;
MAZZELLA, G ;
BAZZOLI, F ;
MORSELLI, AM ;
RODA, E ;
BARBARA, L .
DIGESTIVE DISEASES AND SCIENCES, 1982, 27 (06) :495-502
[2]
Bile Acids Induce Inflammatory Genes in Hepatocytes A Novel Mechanism of Inflammation during Obstructive Cholestasis [J].
Allen, Katryn ;
Jaeschke, Hartmut ;
Copple, Bryan L. .
AMERICAN JOURNAL OF PATHOLOGY, 2011, 178 (01) :175-186
[3]
Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS [J].
Alnouti, Yazen ;
Csanaky, Ivan L. ;
Klaassen, Curtis D. .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 873 (02) :209-217
[4]
[Anonymous], OB AC
[5]
[Anonymous], NOR AC TREATM PRIM S
[6]
[Anonymous], URS
[7]
Bile Acids and Nonalcoholic Fatty Liver Disease: Molecular Insights and Therapeutic Perspectives [J].
Arab, Juan P. ;
Karpen, Saul J. ;
Dawson, Paul A. ;
Arrese, Marco ;
Trauner, Michael .
HEPATOLOGY, 2017, 65 (01) :350-362
[8]
Efficacy, patient-reported outcomes and safety profile of ATX-101 (deoxycholic acid), an injectable drug for the reduction of unwanted submental fat: results from a phase III, randomized, placebo-controlled study [J].
Ascher, B. ;
Hoffmann, K. ;
Walker, P. ;
Lippert, S. ;
Wollina, U. ;
Havlickova, B. .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2014, 28 (12) :1707-1715
[9]
Barrett KE, 2012, GANONGS REV MED PHYS, V24, P509
[10]
Urinary Bile Acids as Biomarkers for Liver Diseases II. Signature Profiles in Patients [J].
Bathena, Sai Praneeth R. ;
Thakare, Rhishikesh ;
Gautam, Nagsen ;
Mukherjee, Sandeep ;
Olivera, Marco ;
Meza, Jane ;
Alnouti, Yazen .
TOXICOLOGICAL SCIENCES, 2015, 143 (02) :308-318